Quantcast
Viewing all articles
Browse latest Browse all 615

Takeda Announces Approval of Prophylactic Indication for VWD Therapy

Takeda recently announced that the U.S. Food and Drug Administration (FDA) has approved VONVENDI® for routine prophylaxis to reduce the frequency of bleeding episodes in adults with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy. Type 3 VWD is the rarest and most severe form of the disease.

VONVENDI® is the only currently available recombinant von Willebrand factor therapy on the market.


Viewing all articles
Browse latest Browse all 615

Trending Articles